Literature DB >> 8227594

Intranasal midazolam for claustrophobia in MRI.

M L Moss1, P A Buongiorno, V A Clancy.   

Abstract

The authors present their preliminary results using intranasal midazolam for claustrophobic MRI patients. This route of administration reduced the necessity for intravenous sedation from 67 to 17% in this select group of patients. The only side effect encountered was a burning sensation of the nasal mucosa. Further investigation is necessary to determine the efficacy of intranasal midazolam in claustrophobic patients scheduled for MR examinations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8227594     DOI: 10.1097/00004728-199311000-00029

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  3 in total

1.  Low-dose intranasal versus oral midazolam for routine body MRI of claustrophobic patients.

Authors:  Frank T C Tschirch; Kerstin Göpfert; Johannes M Fröhlich; Genevieve Brunner; Dominik Weishaupt
Journal:  Eur Radiol       Date:  2006-11-09       Impact factor: 5.315

2.  Midazolam pharmacokinetics following intravenous and buccal administration.

Authors:  R Schwagmeier; S Alincic; H W Striebel
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

3.  Comparison of oral and buccal midazolam for pediatric dental sedation: a randomized, cross-over, clinical trial for efficacy, acceptance and safety.

Authors:  Sara Tavassoli-Hojjati; Majid Mehran; Roza Haghgoo; Monireh Tohid-Rahbari; Rahil Ahmadi
Journal:  Iran J Pediatr       Date:  2014-04       Impact factor: 0.364

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.